Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized controlled study evaluating the efficacy and safety of
HGXJT in combination with ICI-based standard treatment in lung cancer patients with bone
metastases. Enrolled participates will randomly receive HGXJT or placebo during the first 4-6
cycles of ICI-based standard treatment.
Phase:
N/A
Details
Lead Sponsor:
Guangzhou University of Traditional Chinese Medicine